In Q1 2026, Blackstone's distributable earnings of $1.36 per share exceeded analysts' expectations, highlighting its financial resilience in a tough market where competitors like KKR and Apollo have experienced significant losses. The firm also strategically committed $400 million to develop Teva Pharmaceutical's autoimmune drug, 'duvakitug', positioning itself for potential future earnings through milestone payments and royalties. Meanwhile, Blackstone's investment in Jersey Mike's and its collaborative financing efforts signal a proactive approach to strengthening its portfolio.
“The stock has come back up and done pretty well during the past month, and now it’s trading just below Morningstar’s $145 fair value.”
“The stock is up 17% from where we recommended it, putting it solidly in 3-star territory.”
“Those stocks have tumbled by an average of 31% this year, and are each among the worst performers in the S&P 500.”
“Blackstone · made a commitment to · Teva Pharmaceutical Industries Ltd. · $400 million”
“Blackstone · committed · fund development of Teva's drug duvakitug · $400 million”
“Blackstone · stands to receive · milestone payments and royalties · on worldwide sales of duvakitug”
“Blackstone · acquired a majority stake in Jersey Mike's · in 2024 · for around $8 billion”
“Blackstone · acquired a majority stake in · Jersey Mike's · for around $8 billion”
“Related Digital and Blackstone · secured · financing · $16 billion”
“Blackstone · contributed · equity · about $2 billion”
“Blackstone Inc.-backed QTS · sold bonds · to fund a Microsoft Corp.-tied facility · $4.6 billion”
“Blackstone’s BX first-quarter 2026 distributable earnings · surpassed the Zacks Consensus Estimate · $1.33 · $1.36 per share”
.svg&width=160)
